You are using an outdated browser. Please upgrade your browser to improve your experience
EMEA: +44 (0) 1869 255758
13th Mar 2019
EMEA sales & customer support+44 (0) 1869 255758
US sales & customer support+1 (800) 450 2403
Email sales & customer firstname.lastname@example.org
Bevacizumab has been added to the list based on a formal requirement by the US Food and Drug Administration (FDA) that the chemical be identified or labeled as causing reproductive toxicity (developmental and female endpoints).
Businesses are required to provide a clear and reasonable warning before knowingly and intentionally exposing anyone to Prop65 listed chemicals one year after being added to the list.
Get in touch to find out how we can help with your compliance requirements
+44 (0) 1869 255758
US: +1 (800) 450 2403 /
ECHA publishes report on enforcement with authorisation requirement of REACH
8th Mar 2023Read article